AbCellera Biologics Inc. (ABCL) P/E Ratio History
Historical price-to-earnings valuation from 2020 to 2022
Loading P/E history...
ABCL Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, AbCellera Biologics Inc. (ABCL) trades at a price-to-earnings ratio of -9.8x, with a stock price of $4.82 and trailing twelve-month earnings per share of $-0.49.
The current P/E is 129% below its 5-year average of 34.2x. Over the past five years, ABCL's P/E has ranged from a low of 12.5x to a high of 106.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ABCL trades at a 144% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ABCL trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABCL DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABCL P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $74B | 17.1Lowest | 2.70 | +8% | |
| $8B | 25.5 | 1.11Best | -25% | |
| $39B | 127.0 | - | +207%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ABCL Historical P/E Data (2020–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q4 | Sat Dec 31 2022 00:00:00 GM | $10.13 | $0.50 | 20.2x | -41% |
| FY2022 Q3 | Fri Sep 30 2022 00:00:00 GM | $9.89 | $0.79 | 12.5x | -63% |
| FY2022 Q2 | $10.65 | $0.63 | 16.9x | -51% | |
| FY2022 Q1 | $9.75 | $0.64 | 15.2x | -55% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $14.30 | $0.47 | 30.4x | -11% |
| FY2021 Q3 | $20.04 | $0.65 | 30.8x | -10% | |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $22.00 | $0.72 | 30.6x | -11% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $33.96 | $0.76 | 44.8x | +31% |
| FY2020 Q4 | $40.24 | $0.38 | 106.3x | +211% |
Average P/E for displayed period: 34.2x
See ABCL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABCL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ABCL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonABCL — Frequently Asked Questions
Quick answers to the most common questions about buying ABCL stock.
Is ABCL stock overvalued or undervalued?
ABCL trades at -9.8x P/E, below its 5-year average of 34.2x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does ABCL's valuation compare to peers?
AbCellera Biologics Inc. P/E of -9.8x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ABCL's PEG ratio?
ABCL PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2020-2022.